374554-41-3

Usage

General Description

3-Bromo-2-fluorobenzoyl chloride is a chemical compound with the molecular formula C7H3BrFO and a molecular weight of 207.5 g/mol. It is a colorless to pale yellow liquid at room temperature and pressure. 3-Bromo-2-fluorobenzoyl chloride is primarily used in research and pharmaceutical applications as an intermediate in the synthesis of other organic compounds. It is utilized in the production of various pharmaceuticals and agrochemicals. 3-Bromo-2-fluorobenzoyl chloride is a highly reactive and corrosive compound and should be handled and stored with proper safety precautions. It is also known by the chemical names 2-Fluoro-3-bromobenzoyl chloride and Benzenecarbonyl chloride, 2-bromo-3-fluoro-.

InChI:InChI=1/C7H3BrClFO/c8-5-3-1-2-4(6(5)10)7(9)11/h1-3H

Upstream product

• 161957-56-8 3-bromo-2-fluorobenzoic acid 
• 1072-85-1 o-fluorobromobenzene 

Downstream Products

• 374554-43-5 3-bromo-2-fluoro-N-(3-nitrophenyl)benzamide 
• 1160244-34-7 3-bromo-2-fluoro-N-(2-hydroxyphenyl)benzamide 
• 680610-73-5 N-methoxy-N-methyl-3-bromo-2-fluorobenzamide 
• 261723-28-8 (3-bromo-2-fluorophenyl)methanamine 
• 1177558-58-5 1,1-dimethylethyl [(3-bromo-2-fluorophenyl)methyl]carbamate 
• 1055880-24-4 N-benzyl-3-bromo-2-fluoro-N-(2-hydroxyethyl)benzamide 
• 871353-25-2 3-bromo-2-fluorophenylamide 

Relevant academic research and scientific papers

ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF

The disclosure relates to compounds that act as an allosteric inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.

TRICYCLIC ASK1 INHIBITORS

Provided herein are compounds, preferably ASK1 inhibitor compounds, compositions thereof, and methods of their preparation, and methods of inhibiting ASK1 and methods for treating disorders mediated by ASK1.

Synthesis and nematicidal activities of 1,2,3-benzotriazin-4-one derivatives containing thiourea and acylthiourea against Meloidogyne incognita

Two series of novel 1,2,3-benzotriazin-4-one derivatives containing thiourea and acylthiourea were designed and synthesized. The bioassay results showed that most of the test compounds showed good nematicidal activity against M. incognita at the concentration of 10.0?mg?L?1 in vivo. The compounds A13, A17 and B3 showed excellent nematicidal activity on the second stage juveniles of the root-knot nematode with the inhibition rate of 51.3%, 58.3% and 51.3% at the concentration of 1.0?mg?L?1 respectively. It suggested that the structure of 1,2,3-benzotriazin-4-one derivatives containing thiourea and acylthiourea could be optimized further.

Analogues of morphanthridine and the tear gas dibenz[ b, f ][1,4]oxazepine (CR) as extremely potent activators of the human transient receptor potential ankyrin 1 (TRPA1) channel

The TRPA1 channel can be considered as a key biological sensor to irritant chemicals. In this paper, the discovery of 11H-dibenz[b,e]azepines (morphanthridines) and dibenz[b,f][1,4]oxazepines is described as extremely potent agonists of the TRPA1 receptor. This has led to the discovery that most of the known tear gases are potent TRPA1 activators. The synthesis and biological activity of a number of substituted morphanthridines and dibenz[b,f][1,4]oxazepines have given insight into the SAR around this class of TRPA1 agonists, with EC50 values ranging from 1 μM to 0.1 nM. Compounds 6 and 32 can be considered as the most potent TRPA1 agonists known to date, with 6 now being used successfully as a screening tool in the discovery of TRPA1 antagonists. The use of ligands such as 6 and 32 as pharmacological tools may contribute to the basic knowledge of the TRPA1 channel and advance the development of TRPA1 antagonists as potential treatment for conditions involving TRPA1 activation, including asthma and pain.

DIBENZOAZEPINE AND DIBENZOOXAZEPINE TRPA1 AGONISTS

The present invention is related to novel tricyclic compounds of formula (I) having TRPA1 receptor agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use as pharmacologi

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use as dual chromaphores having inhibitory activity against PDE4 and muscarinic acetylcholine receptors (mAChRs), and thus being useful for treating respiratory diseases.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

BENZOXAZEPINE DERIVATIVES AND USE THEREOF

Compounds represented by the general formula (I): wherein each symbol is as defined in the description [with the proviso that 9-chloro-7-(1,1-dimethylethyl)-2,3,4,5-tetrahydro-1,4-benz-oxazepine and N-[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1,4-benz-oxazepin-7-yl)-5-oxazolidinyl]methyl]acetamide are excluded], salts of the same, and prodrugs thereof have selective activation effect on serotonin 5-HT2C receptor and are useful as preventive and therapeutic agents for lower urinary tract diseases, obesity, and/or pelvic organ prolapse.

DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS

The present invention is directed to novel compounds of Formula's (I) - (VI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of and/or prophylaxis of respiratory diseases, including inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

NEW DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION

The present invention relates to compounds which have therapeutic effects against disorders in the central nervous system, and in particular new 4-(ortho, meta-disubstituted phenyl)-1-alkypiperidines and piperazines. (I) wherein R1, R2, R3 and Y are as de